Gilead Provides Update on Phase 3 EVOKE-01 Study

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in…#gileadsciencesinc #phase3 #nsclc #gilead #trodelvy #merdadparsey #phd #gileadsciences #phase2 #worldconference
Source: Reuters: Health - Category: Consumer Health News Source Type: news